Vivek Kumar Kumar

Immunotherapy for cancer treatment has proved to be a very useful technique that helps to boost the immune responses of the host against cancer cells. In this study, the effectiveness of atezolizumab is assessed in Programmed Death-Ligand 1(PD-L1) Positive advanced cancers of Indians. This study was performed using a retrospective analysis on the clinical data of 120 patients that received atezolizumab treatment between 2021 and 2025. Patients with advanced solid malignancies such as non-small cell lung carcinoma (NSCLC), hepaticellular carcinoma (HCC), and triple-negative breast cancer (TNBC) were included in this study. The RECIST 1.1 criteria and CTCAE Version 5.0 recommendations were used to assess the response to therapy, progression-free survival, overall survival, and adverse events linked to the immune system, respectively. Kaplan-Meier survival analysis, chi-square testing, and descriptive statistics were all part of the statistical package. The results demonstrated that patients exhibiting elevated levels of PD-L1 had a substantially better chance of surviving. In total, 76.6% of people were able to keep the sickness at bay, whereas only 48.3% responded. Treatment response is strongly correlated with PD-L1 over-expression (χ² = 9.64, p = 0.002). Adverse reactions experienced by subjects in this study were mostly mild-to-moderate. It was concluded in this study that atezolizumab is an effective and safe immunotherapy drug for treating PD-L1-positive malignancies in Indians.

The mpox virus (MPXV), which is an emergent orthopoxvirus with zoonotic transmission capability, represents a growing public health threat on a global scale due to the recently reported outbreaks in multiple countries after 2022. In view of the rising prevalence of genetically heterogeneous strains, such as Clade I and Clade II, there has been a growing research focus on the molecular aspects of pathogenesis, evolution, transmission, and epidemiology of MPXV clades. The current review focuses on the genome structure, mutations, viral fitness, immune evasiveness, and human-to-human transmission rate associated with MPXV clades. The comparative pathogenicity between the Clade I and Clade II variants is also discussed, with emphasis on the increased virulence and mortality related to Clade I and increased transmissibility of Clade II variants, including Clade IIb. Recent genomic studies have shown that hypermutations caused by the APOBEC3 enzymes, single-nucleotide polymorphism, and adaptive evolution contribute to viral persistence, immune escape, and epidemic spread. Furthermore, the review explains how epidemiologic surveillance efforts, molecular diagnostic tools, genomics techniques, and public health issues related to mpox epidemic response are managed. This information highlights the crucial role of genomics surveillance, timely diagnostics, vaccines, and the One Health approach in future prevention of mpox outbreaks.